Balance Sheet
Cash Flow Statement
AmortizationAmortizatization of IntangiblesAsset Writedowns and ImpairmentCash from Discontinued OperationsCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ascendis Pharma A (ASND) Change in Receivables (2019 - 2025)

Historic Change in Receivables for Ascendis Pharma A (ASND) over the last 7 years, with Q3 2025 value amounting to -$29.1 million.

  • Ascendis Pharma A's Change in Receivables fell 19162.91% to -$29.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$113.7 million, marking a year-over-year decrease of 560426.12%. This contributed to the annual value of -$128.4 million for FY2024, which is 26405.68% down from last year.
  • According to the latest figures from Q3 2025, Ascendis Pharma A's Change in Receivables is -$29.1 million, which was down 19162.91% from -$54.3 million recorded in Q2 2025.
  • In the past 5 years, Ascendis Pharma A's Change in Receivables ranged from a high of $103.1 million in Q1 2025 and a low of -$133.4 million during Q4 2024
  • Over the past 5 years, Ascendis Pharma A's median Change in Receivables value was -$5.6 million (recorded in 2022), while the average stood at -$8.5 million.
  • Per our database at Business Quant, Ascendis Pharma A's Change in Receivables soared by 284089.95% in 2021 and then tumbled by 378647.78% in 2023.
  • Quarter analysis of 5 years shows Ascendis Pharma A's Change in Receivables stood at $3.0 million in 2021, then tumbled by 284.63% to -$5.6 million in 2022, then crashed by 64.71% to -$9.2 million in 2023, then crashed by 1354.25% to -$133.4 million in 2024, then surged by 78.16% to -$29.1 million in 2025.
  • Its last three reported values are -$29.1 million in Q3 2025, -$54.3 million for Q2 2025, and $103.1 million during Q1 2025.